Ospedale Nord

Taranto, Italy

Ospedale Nord

Taranto, Italy

Time filter

Source Type

Zaja F.,Azienda Ospedaliero Universitaria S. Maria Della Misericordia | Baccarani M.,Institute Of Hematology L A Seragnoli | Mazza P.,Ospedale Nord | Bocchia M.,Ematologia e Trapianti | And 16 more authors.
Blood | Year: 2010

Previous observational studies suggest that rituximab may be useful in the treatment of primary immune thrombocytopenia (ITP). This randomized trial investigated rituximab efficacy in previously untreated adult ITP patients with a platelet count of 20 × 109/L or less. One hundred three patients were randomly assigned to receive 40 mg/d dexamethasone for 4 days with or without 375 mg/m2 rituximab weekly for 4 weeks. Patients who were refractory to dexamethasone alone received salvage therapy with dexamethasone plus rituximab. Sustained response (ie, platelet count ≥ 50 × 10 9/L at month 6 after treatment initiation), evaluable in 101 patients, was greater in patients treated with dexamethasone plus rituximab (n = 49) than in those treated with dexamethasone alone (n = 52; 63% vs 36%, P = .004, 95% confidence interval [95% CI], 0.079-0.455). Patients in the experimental arm showed increased incidences of grade 3 to 4 adverse events (10% vs 2%, P = .082, 95% CI, -0.010 to 0.175), but incidences of serious adverse events were similar in both arms (6% vs 2%, P = .284, 95% CI, -0.035 to 0.119). Dexamethasone plus rituximab was an effective salvage therapy in 56% of patients refractory to dexamethasone. The combination of dexamethasone and rituximab improved platelet counts compared with dexamethasone alone. Thus, combination therapy may represent an effective treatment option before splenectomy. This study is registered at http://clinicaltrials.gov as NCT00770562. © 2010 by The American Society of Hematology.


Skibola C.F.,Comprehensive Cancer Center | Skibola C.F.,University of California at Berkeley | Berndt S.I.,U.S. National Cancer Institute | Vijai J.,Sloan Kettering Cancer Center | And 129 more authors.
American Journal of Human Genetics | Year: 2014

Genome-wide association studies (GWASs) of follicular lymphoma (FL) have previously identified human leukocyte antigen (HLA) gene variants. To identify additional FL susceptibility loci, we conducted a large-scale two-stage GWAS in 4,523 case subjects and 13,344 control subjects of European ancestry. Five non-HLA loci were associated with FL risk: 11q23.3 (rs4938573, p = 5.79 × 10 -20) near CXCR5; 11q24.3 (rs4937362, p = 6.76 × 10 -11) near ETS1; 3q28 (rs6444305, p = 1.10 × 10 -10) in LPP; 18q21.33 (rs17749561, p = 8.28 × 10 -10) near BCL2; and 8q24.21 (rs13254990, p = 1.06 × 10 -8) near PVT1. In an analysis of the HLA region, we identified four linked HLA-DRβ1 multiallelic amino acids at positions 11, 13, 28, and 30 that were associated with FL risk (pomnibus = 4.20 × 10 -67 to 2.67 × 10 -70). Additional independent signals included rs17203612 in HLA class II (odds ratio [ORper-allele] = 1.44; p = 4.59 × 10 -16) and rs3130437 in HLA class I (ORper-allele = 1.23; p = 8.23 × 10 -9). Our findings further expand the number of loci associated with FL and provide evidence that multiple common variants outside the HLA region make a significant contribution to FL risk. © 2014 by The American Society of Human Genetics. All rights reserved.


PubMed | Karolinska Institutet, Genome Institute of Singapore, Dalian Maritime University, Stanford University and 48 more.
Type: Comparative Study | Journal: American journal of human genetics | Year: 2014

Genome-wide association studies (GWASs) of follicular lymphoma (FL) have previously identified human leukocyte antigen (HLA) gene variants. To identify additional FL susceptibility loci, we conducted a large-scale two-stage GWAS in 4,523 case subjects and 13,344 control subjects of European ancestry. Five non-HLA loci were associated with FL risk: 11q23.3 (rs4938573, p = 5.79 10(-20)) near CXCR5; 11q24.3 (rs4937362, p = 6.76 10(-11)) near ETS1; 3q28 (rs6444305, p = 1.10 10(-10)) in LPP; 18q21.33 (rs17749561, p = 8.28 10(-10)) near BCL2; and 8q24.21 (rs13254990, p = 1.06 10(-8)) near PVT1. In an analysis of the HLA region, we identified four linked HLA-DR1 multiallelic amino acids at positions 11, 13, 28, and 30 that were associated with FL risk (pomnibus = 4.20 10(-67) to 2.67 10(-70)). Additional independent signals included rs17203612 in HLA class II (odds ratio [OR(per-allele)] = 1.44; p = 4.59 10(-16)) and rs3130437 in HLA class I (OR(per-allele) = 1.23; p = 8.23 10(-9)). Our findings further expand the number of loci associated with FL and provide evidence that multiple common variants outside the HLA region make a significant contribution to FL risk.


Orciuolo E.,University of Pisa | Buda G.,University of Pisa | Marturano E.,Bone Marrow Unit | Mauro E.,Bone Marrow Unit | And 9 more authors.
Leukemia Research | Year: 2011

The aim of this study was to show a lower incidence of febrile episodes in multiple myeloma patients receiving lenograstim vs. filgrastim after high-dose cyclophosphamide for stem cell mobilization. Patients treated with cyclophosphamide were randomly assigned to receive filgrastim or lenograstim. Primary endpoint was the incidence of febrile episodes.5.1% patients developed a febrile episode, 9.1% with filgrastim and 1.1% with lenograstim. Lenograstim group presented a significantly higher absolute CD34+ cell number compared with the filgrastim group but no differences were detected for collection efficacy. The study demonstrated a lower incidence of febrile episodes with lenograstim compared to filgrastim. © 2010 Elsevier Ltd.

Loading Ospedale Nord collaborators
Loading Ospedale Nord collaborators